0001104659-22-066299.txt : 20220531 0001104659-22-066299.hdr.sgml : 20220531 20220531091652 ACCESSION NUMBER: 0001104659-22-066299 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220531 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Changes in Control of Registrant ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220531 DATE AS OF CHANGE: 20220531 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Checkmate Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001651431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 364813934 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39425 FILM NUMBER: 22980882 BUSINESS ADDRESS: STREET 1: 245 MAIN STREET, 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 978-503-2124 MAIL ADDRESS: STREET 1: 245 MAIN STREET, 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 8-K 1 tm2217167d1_8k.htm FORM 8-K
0001651431 false --12-31 0001651431 2022-05-31 2022-05-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): May 31, 2022

 

 

 

CHECKMATE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39425   36-4813934
(State or other jurisdiction of
incorporation or organization)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

Checkmate Pharmaceuticals, Inc.

 

245 Main Street, 2nd Floor

Cambridge, Massachusetts 02142

(Address of Principal Executive Offices) (Zip Code)

 

(617) 682-3625

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange
on which registered
Common Stock, par value $0.0001 per share   CMPI   The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

x Emerging Growth Company

 

¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Introductory Note

 

As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 19, 2022, Checkmate Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, Regeneron Pharmaceuticals, Inc., a New York corporation (“Parent”), and Scandinavian Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), dated as of April 18, 2022. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions therein, on May 31, 2022, Purchaser completed a cash tender offer (the “Offer”) to acquire all of the issued and outstanding shares of the common stock, par value $0.0001 per share, of the Company (the “Common Stock”) at a price per share of $10.50, to be paid to the seller in cash, without interest (the “Offer Price”) and subject to reduction for any applicable withholding of taxes required by applicable law.

 

The Offer expired at one minute after 11:59 p.m. Eastern Time on May 27, 2022. According to the depositary for the Offer, 18,471,314 shares of Common Stock were validly tendered and not withdrawn in the Offer, representing approximately 83.8% of the outstanding shares of Common Stock. The number of shares of Common Stock tendered satisfied the condition to the Offer that there be validly tendered and not validly withdrawn shares of Common Stock that, considered together with all other shares (if any) beneficially owned by Parent and its affiliates, represent one more share than 50% of the total number of shares of Common Stock outstanding at the time of the expiration of the Offer. On May 31, 2022, all conditions to the Offer having been satisfied or waived, Parent and Purchaser accepted for payment all shares of Common Stock validly tendered and not validly withdrawn.

 

Following the consummation of the Offer, the remaining conditions to the Merger set forth in the Merger Agreement were satisfied, and on May 31, 2022, Purchaser merged with and into the Company, with the Company as the surviving corporation in the merger (the “Merger”). The Merger was completed pursuant to Section 251(h) of the DGCL, with no stockholder vote required. At the effective time of the Merger (the “Effective Time”), each issued and outstanding share of Common Stock (other than (i) shares of Common Stock with respect to which the holders thereof have properly exercised and perfected demands for appraisal of such shares in accordance with Section 262 the DGCL, (ii) shares of Common Stock that were owned by the Company as treasury stock, and (iii) shares of Common Stock then held by Parent or Purchaser) were converted automatically into and thereafter represent only the right to receive $10.50 in cash, without interest and subject to any applicable withholding of taxes required by applicable law.

 

In addition, by virtue of the Merger and without any action on the part of any holder thereof, each outstanding and unexercised option to purchase shares of Common Stock (a “Company Option”), whether or not vested, that had a per share exercise price that was less than the Merger Consideration (as defined in the Merger Agreement) (an “In the Money Option”) was cancelled and the holder thereof is entitled to receive a cash payment equal to (A) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share under such In the Money Option, multiplied by (B) the total number of shares subject to such In the Money Option immediately prior to the Effective Time.

 

 

 

At the Effective Time, each Company Option other than an In the Money Option that was outstanding and unexercised, whether or not vested, was cancelled with no consideration payable in respect thereof.

 

The foregoing description of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, a copy of which is filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K, filed with the SEC on April 19, 2022, and which is incorporated herein by reference.

 

Item 2.01. Completion of Acquisition or Disposition of Assets

 

As described in the Introductory Note above, on May 31, 2022, Purchaser irrevocably accepted for payment all shares of Common Stock validly tendered and not validly withdrawn pursuant to the Offer on or prior to the expiration of the Offer. On May 31, 2022, the Merger was completed pursuant to Section 251(h) of the DGCL, with no vote of the Company’s stockholders required. Upon the consummation of the Merger, the Company became a wholly owned subsidiary of Parent.

 

The aggregate consideration payable by Purchaser to acquire the shares of Common Stock in the Offer and the Merger, together with the amounts payable in respect of In the Money Options outstanding immediately prior to the Effective Time, is approximately $250 million. Parent and its controlled affiliates advanced to Purchaser the funds necessary to consummate the Offer and the Merger and to pay the related fees and expenses.

 

The information contained in the Introductory Note of this Current Report on Form 8-K is incorporated by reference into this Item 2.01.

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

 

In connection with the consummation of the Merger, the Company notified The Nasdaq Global Market (“NASDAQ”) of the consummation of the Merger and requested that NASDAQ (i) halt trading in the shares of Common Stock, (ii) suspend trading of and delist the shares of Common Stock and (iii) file with the SEC a notification of removal from listing and/or registration on Form 25 to effect the delisting of all shares of Common Stock from NASDAQ and the deregistration of such shares of Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In addition, the Company intends to file a certification and notice of termination of registration on Form 15 with the SEC requesting the termination of registration of the shares of Common Stock under Section 12(g) of the Exchange Act and the suspension of reporting obligations under Sections 13 and 15(d) of the Exchange Act with respect to the shares of Common Stock.

 

Item 3.03. Material Modification to Rights of Security Holders

 

The information set forth in the Introductory Note and Items 2.01, 3.01, 5.01 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.

 

Item 5.01. Changes in Control of Registrant

 

As a result of the completion of the Merger, a change in control of the Company occurred, and the Company became a wholly owned subsidiary of Parent. The information set forth in the Introductory Note and Items 2.01 and 5.02 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01.

 

Item 5.02. Departure of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

At the Effective Time, each of Alan Bash, Peter Colabuono, Keith Flaherty, Alan Fuhrman, Oren K. Isacoff, Michael Powell, Jon Wigginton and Joy Yan resigned and ceased to be directors of the Company and members of any committee of the Company’s Board of Directors. These resignations were not a result of any disagreement between the Company and the directors on any matter relating to the Company’s operations, policies or practices.

 

 

 

Effective immediately following these resignations, Nouhad Husseini became the sole director of the Company. In addition, in connection with the closing of the Merger, the Company’s Board of Directors appointed Nouhad Hussieni as Managing Director and Robert E. Landry as Chief Financial Officer. Information about the new director and executive officers is contained in the Offer to Purchase, dated May 2, 2022, filed by Parent and Purchaser as Exhibit (a)(1)(i) to the Tender Offer Statement on Schedule TO on May 2, 2022, which information is incorporated herein by reference.

 

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

 

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, the Company’s certificate of incorporation and bylaws were each amended and restated in their entirety. Copies of the amended and restated certificate of incorporation and amended and restated bylaws are attached as Exhibit 3.1 and Exhibit 3.2, respectively, to this Current Report on Form 8-K, and are incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits

 

(d)       Exhibits

 

Exhibit   Description
2.1*   Agreement and Plan of Merger, dated as of April 18, 2022, by and among Checkmate Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., and Scandinavian Acquisition Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 19, 2022).
3.1   Fifth Amended and Restated Certificate of Incorporation of Checkmate Pharmaceuticals, Inc. (filed herewith).
3.2   Third Amended and Restated Bylaws of Checkmate Pharmaceuticals, Inc. (filed herewith).
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

* Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the U.S. Securities and Exchange Commission; provided, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules so furnished.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CHECKMATE PHARMACEUTICALS, INC.
     
Date: May 31, 2022 By: /s/ Nouhad Husseini
    Nouhad Husseini
    Managing Director

  

 

 EX-3.1 2 tm2217167d1_ex3-1.htm EXHIBIT 3.1

 

Exhibit 3.1

 

FIFTH AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
CHECKMATE PHARMACEUTICALS, INC.

 

ARTICLE I

 

The name of the corporation is Checkmate Pharmaceuticals, Inc. (the “Corporation”).

 

ARTICLE II

 

The address, including street, number, city, and county, of the registered office of the Corporation in the State of Delaware is the Corporation Trust Company, 1209 Orange Street, City of Wilmington, County of New Castle, State of Delaware 19801. The name of the registered agent of the Corporation in the State of Delaware at such address is The Corporation Trust Company.

 

ARTICLE III

 

The purpose of the Corporation shall be to engage in any lawful act or activity for which corporations may be organized and incorporated under the General Corporation Law of the State of Delaware.

 

ARTICLE IV

 

Section 1     The Corporation shall be authorized to issue 1,000 shares of capital stock, all of which 1,000 shares shall be shares of common stock, par value $0.01 per share (the “Common Stock”).

 

Section 2     Except as otherwise provided by law, the Common Stock shall have the exclusive right to vote for the election of directors and for all other purposes. Each share of the Common Stock shall have one vote and the Common Stock shall vote together as a single class.

 

ARTICLE V

 

Any one or more directors may be removed, with or without cause, by the vote or written consent of the holders of a majority of the issued and outstanding shares of capital stock of the Corporation entitled to be voted in the election of directors.

 

ARTICLE VI

 

In furtherance and not in limitation of those powers conferred by the DGCL, the board of directors of the Corporation is expressly authorized and empowered to make, alter and repeal the by-laws of the Corporation (the “By-Laws”) to the fullest extent permitted by the provisions of the DGCL.

 

ARTICLE VII

 

Meetings of the stockholders shall be held at such place, within or without the State of Delaware as may be designated by, or in the manner provided in, the By-Laws or, if not so designated, at the registered office of the Corporation in the State of Delaware. Elections of directors need not be by written ballot unless and to the extent that the By-Laws so provide.

 

 

 

ARTICLE VIII

 

The Corporation reserves the right at any time from time to time to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, and any other provisions authorized by the laws of the State of Delaware at the time in force may be added or inserted, in the manner now or hereinafter prescribed by law, and all rights, preferences and privileges of whatsoever nature conferred upon stockholders, directors or any other persons whomsoever by and pursuant to this Certificate of Incorporation in its present form or as hereafter amended are granted subject to the right reserved in this Article.

ARTICLE IX

 

Section 1     The personal liability of the directors of the Corporation is hereby eliminated to the fullest extent permitted by the provisions of paragraph (7) of subsection (b) of § 102 of the DGCL, as the same may be amended and supplemented.

 

Section 2     The Corporation shall, to the fullest extent permitted by the provisions of § 145 of the General Corporation Law of the State of Delaware, as the same may be amended and supplemented, indemnify any and all persons whom it shall have power to indemnify under said section from and against any and all of the expenses, liabilities, or other matters referred to in or covered by said section, and the indemnification provided for herein shall not be deemed exclusive of any other rights to which those indemnified may be entitled under any By-Law, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be a director, officer, employee, or agent and shall inure to the benefit of the heirs, executors, and administrators of such a person.

 

Section 3     Any repeal or modification of the clauses in this Article IX shall be prospective only and shall not adversely affect any right or protection of a director, officer, agent or other person existing at the time of, or increase the liability of any director or officer of the Corporation with respect to any acts or omissions of such director occurring prior to, such repeal or modification.

 

 

 

IN WITNESS WHEREOF, the Corporation has caused this Amended and Restated Certificate of Incorporation to be executed on its behalf this 31st day of May, 2022.

 

  CHECKMATE PHARMACEUTICALS, INC.
     
  By: /s/ Alan Bash
    Name: Alan Bash
    Title: Chief Executive Officer

 

[Signature Page to Fifth Amended and Restated Certificate of Incorporation of Checkmate Pharmaceuticals, Inc.]

 

 

 

 EX-3.2 3 tm2217167d1_ex3-2.htm EXHIBIT 3.2

 

Exhibit 3.2

 

THIRD AMENDED AND RESTATED

 

BY-LAWS

 

of

 

CHECKMATE PHARMACEUTICALS, INC.

 

dated as of May 31, 2022

 

 

TABLE OF CONTENTS

 

ARTICLE I

 

OFFICES

 

SECTION 1.    REGISTERED OFFICE 1
SECTION 2.    OTHER OFFICES 1

 

ARTICLE II

 

MEETINGS OF STOCKHOLDERS

 

SECTION 1.    ANNUAL MEETINGS 1
SECTION 2.    SPECIAL MEETINGS 1
SECTION 3.    VOTING 1
SECTION 4.    QUORUM 2
SECTION 5.    NOTICE OF MEETINGS 2
SECTION 6.    ACTION WITHOUT MEETING 2

 

ARTICLE III

 

DIRECTORS

 

SECTION 1.    NUMBER AND TERM 2
SECTION 2.    RESIGNATIONS 2
SECTION 3.    VACANCIES 3
SECTION 4.    REMOVAL 3
SECTION 5.    COMMITTEES 3
SECTION 6.    MEETINGS 3
SECTION 7.    QUORUM 4
SECTION 8.    COMPENSATION 4
SECTION 9.    ACTION WITHOUT MEETING 4

 

ARTICLE IV

 

OFFICERS

 

SECTION 1.    OFFICERS 4
SECTION 2.    MANAGING DIRECTOR 4
SECTION 3.    VICE PRESIDENTS 4
SECTION 4.    TREASURER 4
SECTION 5.    SECRETARY 5
SECTION 6.    ASSISTANT TREASURERS AND ASSISTANT SECRETARIES 5

 

-i-

 

ARTICLE V

 

MISCELLANEOUS

 

SECTION 1.    CERTIFICATES OF STOCK 5
SECTION 2.    LOST CERTIFICATES 5
SECTION 3.    TRANSFER OF SHARES 5
SECTION 4.    STOCKHOLDERS RECORD DATE 6
SECTION 5.    DIVIDENDS 6
SECTION 6.    FISCAL YEAR 6
SECTION 7.    CHECKS 6
SECTION 8.    NOTICE AND WAIVER OF NOTICE 7
SECTION 9.    CORPORATE SEAL 7

ARTICLE VI

 

INDEMNIFICATION

SECTION 1.    DIRECTORS AND OFFICERS 7
SECTION 2.    EMPLOYEES AND OTHER AGENTS 7
SECTION 3.    EXPENSES 7
SECTION 4.    ENFORCEMENT 8
SECTION 5.    NON-EXCLUSIVITY OF RIGHTS 9
SECTION 6.    SURVIVAL OF RIGHTS 9
SECTION 7.    INSURANCE 9
SECTION 8.    AMENDMENTS 9
SECTION 9.    SAVING CLAUSE 9
SECTION 10.    CERTAIN DEFINITIONS 9

ARTICLE VII

 

AMENDMENTS

 

-ii-

 

ARTICLE I

 

OFFICES

 

SECTION 1.            REGISTERED OFFICE – The address, including street, number, city, and county, of the registered office of Checkmate Pharmaceuticals, Inc. (the “Corporation”) in the State of Delaware is the Corporation Trust Company, 1209 Orange Street, City of Wilmington, County of New Castle, State of Delaware 19801; and the name of the registered agent of the corporation in the State of Delaware at such address is Corporation Trust Company.

 

SECTION 2.            OTHER OFFICES – The Corporation may have other offices, either within or without the State of Delaware, at such place or places as the Board of Directors may from time to time select or the business of the Corporation may require.

 

ARTICLE II

MEETINGS OF STOCKHOLDERS

 

SECTION 1.            ANNUAL MEETINGS – Annual meetings of stockholders for the election of directors, and for such other business as may be stated in the notice of the meeting, shall be held at such place, either within or without the State of Delaware, and at such time and date as the Board of Directors, by resolution, shall determine and as set forth in the notice of the meeting. If the Board of Directors fails so to determine the time, date and place of meeting, the annual meeting of stockholders shall be held at the registered office of the Corporation on the first Tuesday in May. If the date of the annual meeting shall fall upon a legal holiday, the meeting shall be held on the next succeeding business day. At each annual meeting, the stockholders entitled to vote shall elect a Board of Directors and they may transact such other corporate business as shall be stated in the notice of the meeting.

 

SECTION 2.            SPECIAL MEETINGS – Special meetings of the stockholders for any purpose or purposes may be called by the Chairman, the Managing Director or the Secretary, or by resolution of the Board of Directors.

 

SECTION 3.            VOTING – Each stockholder entitled to vote in accordance with the terms of the Certificate of Incorporation of the Corporation and these By-Laws may vote in person or by proxy, but no proxy shall be voted after three years from its date unless such proxy provides for a longer period. All elections for directors shall be decided by plurality vote; all other questions shall be decided by majority vote except as otherwise provided by the Certificate of Incorporation or the laws of the State of Delaware.

 

A complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, with the address of each, and the number of shares held by each, shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten days prior to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not so specified, at the place where the meeting is to be held. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is entitled to be present.

 

 

SECTION 4.            QUORUM – Except as otherwise required by law, by the Certificate of Incorporation of the Corporation or by these By-Laws, the presence, in person or by proxy, of stockholders holding shares constituting a majority of the voting power of the Corporation shall constitute a quorum at all meetings of the stockholders. In case a quorum shall not be present at any meeting, a majority in interest of the stockholders entitled to vote thereat, present in person or by proxy, shall have the power to adjourn the meeting from time to time, without notice other than announcement at the meeting, until the requisite amount of stock entitled to vote shall be present. At any such adjourned meeting at which the requisite amount of stock entitled to vote shall be represented, any business may be transacted that might have been transacted at the meeting as originally noticed; but only those stockholders entitled to vote at the meeting as originally noticed shall be entitled to vote at any adjournment or adjournments thereof.

 

SECTION 5.            NOTICE OF MEETINGS – Written notice, stating the place, date and time of the meeting, and the general nature of the business to be considered, shall be given to each stockholder entitled to vote thereat, at his or her address as it appears on the records of the Corporation, not less than ten nor more than sixty days before the date of the meeting. No business other than that stated in the notice shall be transacted at any meeting without the unanimous consent of all the stockholders entitled to vote thereat.

 

SECTION 6.            ACTION WITHOUT MEETING – Unless otherwise provided by the Certificate of Incorporation of the Corporation, any action required or permitted to be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing.

 

ARTICLE III

DIRECTORS

 

SECTION 1.            NUMBER AND TERM – The business and affairs of the Corporation shall be managed under the direction of a Board of Directors which shall consist of not less than one person. The exact number of directors shall initially be one and may thereafter be fixed from time to time by the Board of Directors. Directors shall be elected at the annual meeting of stockholders and each director shall be elected to serve until his or her successor shall be elected and shall qualify. A director need not be a stockholder.

 

SECTION 2.            RESIGNATIONS – Any director may resign at any time. Such resignation shall be made in writing, and shall take effect at the time specified therein, and if no time be specified, at the time of its receipt by the Chairman, the Managing Director or the Secretary. The acceptance of a resignation shall not be necessary to make it effective.

 

-2-

 

SECTION 3.            VACANCIES – If the office of any director becomes vacant, the remaining directors in the office, though less than a quorum, by a majority vote, may appoint any qualified person to fill such vacancy, who shall hold office for the unexpired term and until his or her successor shall be duly chosen. If the office of any director becomes vacant and there are no remaining directors, the stockholders, by the affirmative vote of the holders of shares constituting a majority of the voting power of the Corporation, at a special meeting called for such purpose, may appoint any qualified person to fill such vacancy.

 

SECTION 4.            REMOVAL – Except as hereinafter provided, any director or directors may be removed either for or without cause at any time by the affirmative vote of the holders of a majority of the voting power entitled to vote for the election of directors, at an annual meeting or a special meeting called for the purpose, and the vacancy thus created may be filled, at such meeting, by the affirmative vote of holders of shares constituting a majority of the voting power of the Corporation.

 

SECTION 5.            COMMITTEES – The Board of Directors may, by resolution or resolutions passed by a majority of the whole Board of Directors, designate one or more committees, each committee to consist of one or more directors of the Corporation.

 

Any such committee, to the extent provided in the resolution of the Board of Directors, or in these By-Laws, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation.

 

SECTION 6.            MEETINGS – The newly elected director(s) may hold their first meeting for the purpose of organization and the transaction of business, if a quorum be present, immediately after the annual meeting of the stockholders; or the time and place of such meeting may be fixed by consent of all the Directors.

 

Regular meetings of the Board of Directors may be held without notice at such places and times as shall be determined from time to time by resolution of the Board of Directors.

 

Special meetings of the Board of Directors may be called by the Chairman or the Managing Director or by the Secretary on the written request of any director, on at least one day’s notice to each director (except that notice to any director may be waived in writing by such director) and shall be held at such place or places as may be determined by the Board of Directors, or as shall be stated in the notice of the meeting.

 

Unless otherwise restricted by the Certificate of Incorporation of the Corporation or these By-Laws, members of the Board of Directors, or any committee designated by the Board of Directors, may participate in any meeting of the Board of Directors or any committee thereof by means of a conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in person at the meeting.

 

-3-

 

SECTION 7.            QUORUM – A majority of the Directors shall constitute a quorum for the transaction of business. If at any meeting of the Board of Directors there shall be less than a quorum present, a majority of those present may adjourn the meeting from time to time until a quorum is obtained, and no further notice thereof need be given other than by announcement at the meeting which shall be so adjourned. The vote of the majority of the Directors present at a meeting at which a quorum is present shall be the act of the Board of Directors unless the Certificate of Incorporation of the Corporation or these By-Laws shall require the vote of a greater number.

 

SECTION 8.            COMPENSATION – Directors shall not receive any stated salary for their services as directors or as members of committees, but by resolution of the Board of Directors a fixed fee and expenses of attendance may be allowed for attendance at each meeting. Nothing herein contained shall be construed to preclude any director from serving the Corporation in any other capacity as an officer, agent or otherwise, and receiving compensation therefor.

 

SECTION 9.            ACTION WITHOUT MEETING – Any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting if a written consent thereto is signed by all members of the Board of Directors or of such committee, as the case may be, and such written consent is filed with the minutes of proceedings of the Board of Directors or such committee.

 

ARTICLE IV

OFFICERS

 

SECTION 1.            OFFICERS – The officers of the Corporation shall be a Managing Director and a Secretary, all of whom shall be elected by the Board of Directors and shall hold office until their successors are duly elected and qualified. In addition, the Board of Directors may elect a Treasurer and such Vice Presidents, Assistant Secretaries and Assistant Treasurers as it may deem proper. The Board of Directors may appoint such other officers and agents as it may deem advisable, who shall hold their offices for such terms and shall exercise such powers and perform such duties as shall be determined from time to time by the Board of Directors.

 

SECTION 2.            MANAGING DIRECTOR – The Managing Director shall be the Chief Operating Officer of the Corporation. He or she shall have the general powers and duties of supervision and management usually vested in the office of President of a corporation.

 

SECTION 3.            VICE PRESIDENTS – Vice Presidents, if any, shall have such powers and shall perform such duties as shall be assigned to them, respectively, by the Board of Directors.

 

SECTION 4.            TREASURER – The Treasurer, if any, shall be the Chief Financial Officer of the Corporation. He or she shall have the custody of the Corporate funds and securities and shall keep full and accurate account of receipts and disbursements in books belonging to the Corporation. He or she shall deposit all moneys and other valuables in the name and to the credit of the Corporation in such depositaries as may be designated by the Board of Directors. He or she shall disburse the funds of the Corporation as may be ordered by the Board of Directors, the Chairman or the Managing Director, taking proper vouchers for such disbursements. He or she shall render to the Chairman, the Managing Director and Board of Directors at the regular meetings of the Board of Directors, or whenever they may request it, an account of all his or her transactions as Treasurer and of the financial condition of the Corporation. If required by the Board of Directors, he or she shall give the Corporation a bond for the faithful discharge of his or her duties in such amount and with such surety as the Board of Directors shall prescribe. If there is no Treasurer appointed by the Board of Directors of the Corporation, the duties of Treasurer shall be vested in the Managing Director.

 

-4-

 

SECTION 5.            SECRETARY – The Secretary shall give, or cause to be given, notice of all meetings of stockholders and of the Board of Directors and all other notices required by law or by these By-Laws, and in case of his or her absence or refusal or neglect so to do, any such notice may be given by any person thereunto directed by the Chairman or the Managing Director, or by the Board of Directors, upon whose request the meeting is called as provided in these By-Laws. He or she shall record all the proceedings of the meetings of the Board of Directors, any committees thereof and the stockholders of the Corporation in a book to be kept for that purpose, and shall perform such other duties as may be assigned to him or her by the Board of Directors, the Chairman or the Managing Director.

 

SECTION 6.            ASSISTANT TREASURERS AND ASSISTANT SECRETARIES – Assistant Treasurers and Assistant Secretaries, if any, shall be elected and shall have such powers and shall perform such duties as shall be assigned to them, respectively, by the Board of Directors.

 

ARTICLE V

MISCELLANEOUS

 

SECTION 1.            CERTIFICATES OF STOCK – Each stockholder shall be entitled to a certificate of stock certifying the number of shares owned by such stockholder in the Corporation. Certificates of stock of the Corporation shall be of such form and device as the Board of Directors may from time to time determine. If authorized by the Board of Directors, the Corporation may issue some or all of the shares of stock of the Corporation without certificates.

 

SECTION 2.            LOST CERTIFICATES – A new certificate of stock may be issued in the place of any certificate theretofore issued by the Corporation, alleged to have been lost or destroyed, and the Board of Directors may, in its discretion, require the owner of the lost or destroyed certificate, or such owner’s legal representatives, to give the Corporation a bond, in such sum as they may direct, not exceeding double the value of the stock, to indemnify the Corporation against any claim that may be made against it on account of the alleged loss of any such certificate, or the issuance of any such new certificate.

 

SECTION 3.            TRANSFER OF SHARES – The shares of stock of the Corporation shall be transferable only upon its books by the holders thereof in person or by their duly authorized attorneys or legal representatives, and upon such transfer the old certificates shall be surrendered to the Corporation by the delivery thereof to the person in charge of the stock and transfer books and ledgers, or to such other person as the Board of Directors may designate, by whom they shall be cancelled, and new certificates shall thereupon be issued. A record shall be made of each transfer and whenever a transfer shall be made for collateral security, and not absolutely, it shall be so expressed in the entry of the transfer.

 

-5-

 

SECTION 4.            STOCKHOLDERS RECORD DATE – In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors and which record date: (1) in the case of determination of stockholders entitled to vote at any meeting of stockholders or adjournment thereof, shall, unless otherwise required by law, not be more than sixty nor less than ten days before the date of such meeting; (2) in the case of determination of stockholders entitled to express consent to corporate action in writing without a meeting, shall not be more than ten days from the date upon which the resolution fixing the record date is adopted by the Board of Directors; and (3) in the case of any other action, shall not be more than sixty days prior to such other action. If no record date is fixed: (1) the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held; (2) the record date for determining stockholders entitled to express consent to corporate action in writing without a meeting when no prior action of the Board of Directors is required by law, shall be the first day on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Corporation in accordance with applicable law, or, if prior action by the Board of Directors is required by law, shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action; and (3) the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.

 

SECTION 5.            DIVIDENDS – Dividends upon the capital stock of the Corporation shall in the discretion of the Board of Directors from time to time be declared by the Board of Directors out of funds legally available therefor after setting aside of proper reserves.

 

SECTION 6.            FISCAL YEAR – The fiscal year of the Corporation shall be determined by resolution of the Board of Directors.

 

SECTION 7.            CHECKS – All checks, drafts or other orders for the payment of money, notes or other evidences of indebtedness issued in the name of the Corporation shall be signed by such officer or officers, or agent or agents, of the Corporation, and in such manner as shall be determined from time to time by resolution of the Board of Directors.

 

-6-

 

SECTION 8.            NOTICE AND WAIVER OF NOTICE – Whenever any notice is required to be given under these By-Laws, personal notice is not required unless expressly so stated, and any notice so required shall be deemed to be sufficient if given by depositing the same in the United States mail, postage prepaid, addressed to the person entitled thereto at his or her address as it appears on the records of the Corporation, and such notice shall be deemed to have been given on the day of such mailing. Stockholders not entitled to vote shall not be entitled to receive notice of any meetings except as otherwise provided by law. Whenever any notice is required to be given under the provisions of any law, or under the provisions of the Certificate of Incorporation of the Corporation or of these By-Laws, a waiver thereof, in writing and signed by the person or persons entitled to said notice, whether before or after the time stated therein, shall be deemed equivalent to such required notice.

 

SECTION 9.            CORPORATE SEAL – The corporate seal shall have inscribed thereon the name of the Corporation and the words “Corporate Seal, Delaware.”

 

ARTICLE VI

INDEMNIFICATION

 

SECTION 1.            DIRECTORS AND OFFICERS – The Corporation shall indemnify its directors and officers to the extent not prohibited by the Delaware General Corporation Law (the “DGCL”) or any other applicable law; provided, however, that the Corporation may modify the extent of such indemnification by individual contracts with its directors and officers; and, provided, further, that the Corporation shall not be required to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless (i) such indemnification is expressly required to be made by law, (ii) the proceeding was authorized by the Board of Directors of the Corporation, (iii) such indemnification is provided by the Corporation, in its sole discretion, pursuant to the powers vested in the Corporation under the DGCL or any other applicable law or (iv) such indemnification is required to be made under subsection (d).

 

SECTION 2.            EMPLOYEES AND OTHER AGENTS – The Corporation shall have power to indemnify its employees and other agents as set forth in the DGCL or any other applicable law. The Board of Directors shall have the power to delegate the determination of whether indemnification shall be given to any such person to such officers or other persons as the Board of Directors shall determine.

 

SECTION 3.            EXPENSES – The Corporation shall advance to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was a director or officer, of the Corporation, or is or was serving at the request of the Corporation as a director or officer of another Corporation, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request therefor, all expenses incurred by any director or officer in connection with such proceeding; provided, however, that if the DGCL requires, an advancement of expenses incurred by a director or officer in his or her capacity as a director or officer (and not in any other capacity in which service was or is rendered by such indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon delivery to the Corporation of an undertaking (hereinafter an “undertaking”), by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal (hereinafter a “final adjudication”) that such indemnitee is not entitled to be indemnified for such expenses under this section or otherwise.

 

-7-

 

Notwithstanding the foregoing, unless otherwise determined pursuant to paragraph (e) of this section, no advance shall be made by the Corporation to an officer of the Corporation (except by reason of the fact that such officer is or was a director of the Corporation in which event this paragraph shall not apply) in any action, suit or proceeding, whether civil, criminal, administrative or investigative, if a determination is reasonably and promptly made (i) by a majority vote of directors who were not parties to the proceeding, even if not a quorum, or (ii) by a committee of such directors designated by a majority vote of such directors, even though less than a quorum, or (iii) if there are no such directors, or such directors so direct, by independent legal counsel in a written opinion, that the facts known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the Corporation.

 

SECTION 4.            ENFORCEMENT – Without the necessity of entering into an express contract, all rights to indemnification and advances to directors and officers under this Bylaw shall be deemed to be contractual rights and be effective to the same extent and as if provided for in a contract between the Corporation and the director or officer. Any right to indemnification or advances granted by this section to a director or officer shall be enforceable by or on behalf of the person holding such right in any court of competent jurisdiction if (i) the claim for indemnification or advances is denied, in whole or in part, or (ii) no disposition of such claim is made within ninety (90) days of request therefor. To the extent permitted by law, the claimant in such enforcement action, if successful in whole or in part, shall be entitled to be paid also the expense of prosecuting the claim. In connection with any claim for indemnification, the Corporation shall be entitled to raise as a defense to any such action that the claimant has not met the standards of conduct that make it permissible under the DGCL or any other applicable law for the Corporation to indemnify the claimant for the amount claimed. In connection with any claim by an officer of the Corporation (except in any action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such officer is or was a director of the Corporation) for advances, the Corporation shall be entitled to raise a defense as to any such action clear and convincing evidence that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the Corporation, or with respect to any criminal action or proceeding that such person acted without reasonable cause to believe that his conduct was lawful. Neither the failure of the Corporation (including its Board of Directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because the officer or director has met the applicable standard of conduct set forth in the DGCL or any other applicable law, nor an actual determination by the Corporation (including its Board of Directors, independent legal counsel or its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that claimant has not met the applicable standard of conduct. In any suit brought by a director or officer to enforce a right to indemnification or to an advancement of expenses hereunder, the burden of proving that the director or officer is not entitled to be indemnified, or to such advancement of expenses, under this section or otherwise shall be on the Corporation.

 

-8-

 

SECTION 5.            NON-EXCLUSIVITY OF RIGHTS – The rights conferred on any person by this Bylaw shall not be exclusive of any other right which such person may have or hereafter acquire under any applicable statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person's official capacity and as to action in another capacity while holding office. The Corporation is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents respecting indemnification and advances, to the fullest extent not prohibited by the DGCL, or by any other applicable law.

 

SECTION 6.            SURVIVAL OF RIGHTS – The rights conferred on any person by this Bylaw shall continue as to a person who has ceased to be a director, officer, employee or other agent and shall inure to the benefit of the heirs, executors and administrators of such a person.

 

SECTION 7.            INSURANCE – To the fullest extent permitted by the DGCL or any other applicable law, the Corporation, upon approval by the Board of Directors, may purchase insurance on behalf of any person required or permitted to be indemnified pursuant to this section.

 

SECTION 8.            AMENDMENTS – Any repeal or modification of this section shall only be prospective and shall not affect the rights under this Bylaw in effect at the time of the alleged occurrence of any action or omission to act that is the cause of any proceeding against any agent of the Corporation.

 

SECTION 9.            SAVING CLAUSE – If this Bylaw or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify each director and officer to the full extent not prohibited by any applicable portion of this section that shall not have been invalidated, or by any other applicable law. If this section shall be invalid due to the application of the indemnification provisions of another jurisdiction, then the Corporation shall indemnify each director and officer to the full extent under any other applicable law.

 

SECTION 10.        CERTAIN DEFINITIONS – For the purposes of this Bylaw, the following definitions shall apply:

 

(a)               The term “proceeding” shall be broadly construed and shall include, without limitation, the investigation, preparation, prosecution, defense, settlement, arbitration and appeal of, and the giving of testimony in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative.

 

-9-

 

(b)               The term “expenses” shall be broadly construed and shall include, without limitation, court costs, attorneys' fees, witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any nature or kind incurred in connection with any proceeding.

 

(c)               The term the “Corporation” shall include, in addition to the resulting Corporation, any constituent Corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent Corporation, or is or was serving at the request of such constituent Corporation as a director, officer, employee or agent of another Corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this section with respect to the resulting or surviving Corporation as he would have with respect to such constituent Corporation if its separate existence had continued.

 

(d)               References to a “director,” “officer,” “employee,” or “agent” of the Corporation shall include, without limitation, situations where such person is serving at the request of the Corporation as, respectively, a director, officer, employee, trustee or agent of another Corporation, partnership, joint venture, trust or other enterprise.

 

(e)               References to “other enterprises” shall include employee benefit plans; references to “fines” shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to “serving at the request of the Corporation” shall include any service as a director, officer, employee or agent of the Corporation which imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its participants, or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the Corporation” as referred to in this section.

 

ARTICLE VII

AMENDMENTS

 

These By-Laws may be altered, amended or repealed at any annual meeting of the stockholders (or at any special meeting thereof if notice of such proposed alteration, amendment or repeal to be considered is contained in the notice of such special meeting) by the affirmative vote of the holders of shares constituting a majority of the voting power of the Corporation. Except as otherwise provided in the Certificate of Incorporation of the Corporation, the Board of Directors may by majority vote of those present at any meeting at which a quorum is present alter, amend or repeal these By-Laws, or enact such other By-Laws as in their judgment may be advisable for the regulation and conduct of the affairs of the Corporation.

 

-10-

 

 EX-101.SCH 4 cmpi-20220531.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 cmpi-20220531_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 cmpi-20220531_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
May 31, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 31, 2022
Current Fiscal Year End Date --12-31
Entity File Number 001-39425
Entity Registrant Name CHECKMATE PHARMACEUTICALS, INC.
Entity Central Index Key 0001651431
Entity Tax Identification Number 36-4813934
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 245 Main Street
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code 617
Local Phone Number 682-3625
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol CMPI
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 tm2217167d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001651431 2022-05-31 2022-05-31 iso4217:USD shares iso4217:USD shares 0001651431 false --12-31 8-K 2022-05-31 CHECKMATE PHARMACEUTICALS, INC. DE 001-39425 36-4813934 245 Main Street 2nd Floor Cambridge MA 02142 617 682-3625 false false false false Common Stock, par value $0.0001 per share CMPI NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://checkmatepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2217167d1_8k.htm cmpi-20220531.xsd cmpi-20220531_lab.xml cmpi-20220531_pre.xml tm2217167d1_ex3-1.htm tm2217167d1_ex3-2.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2217167d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2217167d1_8k.htm" ] }, "labelLink": { "local": [ "cmpi-20220531_lab.xml" ] }, "presentationLink": { "local": [ "cmpi-20220531_pre.xml" ] }, "schema": { "local": [ "cmpi-20220531.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 0, "nsprefix": "CMPI", "nsuri": "http://checkmatepharma.com/20220531", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2217167d1_8k.htm", "contextRef": "From2022-05-31to2022-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://checkmatepharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2217167d1_8k.htm", "contextRef": "From2022-05-31to2022-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://checkmatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-066299-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-066299-xbrl.zip M4$L#!!0 ( !E*OU0X(O[Q00, H, 1 8VUP:2TR,#(R,#4S,2YX ME7=F-K],P0,\@%1.\Z;BELH. >\)G?-1T;OKXM-_J M=!ST]>3#>V2>QD>,T1F#P*^CMO!PAP_%,?I.0ZBC<^ @J1;R&-W2(+86<<8" MD*@EPB@ #<:11JJC6LFM#A#&6^C> O>%O.EU9KICK2-5)V0RF92X>*83(1]5 MR1/A=H)]376L9FKE:3E[MJ-?,.7-R ?TM#;Y,NVQ^Q'PP[A+JP_>';WK]@>7 M_N^'WL'YS\>I#K^]#*Y#VGXYC ]$NWW:(I?D[OYNTKL^2T,VE#>&D")S&%PU M'5M?5MZD6A)R1"KELDON+[K]!.>DP/HT8/RQ".X>'1V1Q)M#5Y#3@0QRZ2JQ M[@%5,%,V7K8!S[C2E'NO\+Z>$1;!-9(Z7T%9(?1S"F4YU(IIP+T_)F[C*+M441,SUM#.\:]O#K4@3PP]2![,(,V\80 M%D-:PMP;#F)^TTF75LQ()W(^#!EG2D(@5^)?\ M)%E'$I3A)45TC2$C9I U)(\&7ASLQIFG4DC)#/EFS;#%$R>'7;%$U' M,7OU.9EM+&'8=+PP8C@_I5^FM))IEQQBI3<,7K+SR[N1!<\;$W8K9@[IC15_CS379*8[\!N M2>2\/9)8>WD79:#6$^P2I\MM0V_\$&P,7\@D$&B56_!<:Y]T5C\;;\@G$=LC MH5>'[6M)K)"5+EN=RH:D_L9,WM5>+>*)F&OYDE2X99,L4O*79#MV/IGE7X#M M#B5GI0=B_PK>T!S%/Q7[)K*^-1HDU33+/U!+ P04 " 92K]4;8>PW?\* M !LAP %0 &-M<&DM,C R,C U,S%?;&%B+GAM;,V=7U/KN!G&[SO3[Z"F M-^W,"3F!MC.PA]WAY,!.9EF@).=LVYW.CF*+X,&1J.Q \NTKV99C2WIM0Z>2 MN(!@/:_\R/I%DO](_O3#;I.B%\*SA-'ST?3HXP@1&K$XH>OST=?%^&(QF\]' M*,LQC7'**#D?43;ZX?O?_PZ)GT]_&(_154+2^ Q]8=%X3A_8=^@&;\@9^I%0 MPG'.^'?H&TZW<@N[2E+"T8QMGE.2$Y%0[O@,_?5H>K)"X_& ?+\1&C/^]7Y> MY_N8Y\_9V63R^OIZ1-D+?F7\*3N*V&98AHLV]NT&@ M0OXW5K*QW#2>'H]/ID>[+!ZI@U\<04%',LWS_+%#*$DG"J-KVR,F# MW4S*^43&3RA9XYS$G55!4U'Y_U" 9KSS(BQ9CM-WF6]&.K=]0]YWQ ]Q[H^T:.?) M^XYT(_+_8CLW+;_Y\-J/:RHW7HM/+8MDEXL.C,3*I,RBHP4N]E!T#%7>=>XL M:N6;RM:<<;/LLFF^%PQ#Z9H-P*J.AR8+BA"[-Q"26NZ?DR7'-$MD8]8+BBEU M?AH"F#5.231=4*P YN!3E5KOGY;%(TE3><\ T_Z&Q29V30QL6&?&5 9%#6@/ MY*:(0%5(6.A$A MU+[AN$JR"*>EGRNQ+>LHHD7K&A+0K@Z*(0P*%L@="$P9H+@I0KQ#\T^"^3!D M&DH_P!A6[;C4L@!AT;WUH2+UWD"9;3EO.8=['UCJ[&9NC]GZOBZ@"P*6'G/& MW=Y2WH+%8V]T2?,DW\OG\6ZVFQ7AE@*:$E=\0.84%WIZ$#P IG0.2AF2.E0* MO=6^NJM <_D@)%@D7>:6 KO)-@EM34 T6(T!1!RTQ7.IWJB8B5:*XW1.8[+[ MB>S!LADZMUP -MM@:** R+ [ ]"HQ*A0(R'W!L<=3S:8[Q=)U--MF$*W>$!& MVWSHJH :P!A%1JM)C/?/H,"0BR(3X! MU%JA'\IG6A"3 L7UE X)R\H;@G_L$Y M&0K.2=#@G+P+'%'YWMN,H:W/F!D@!S? MR!#?J!2#K5M^Q]E+0B-X& W)O4 #F+:2HVG#P\=NL(^A>I"LXGR#5 W6>[\L M2N:GM6F;M#AN94NT;BSN6Y3C]5_+<>9)N%WM!Q&K8"DI+&1XN M-GM]T)0Q2 3Y.NFNL)4W0*S3U;1T=U..+;8.4XX;B4& 8'-D3CDNKZZ4(A]5 M+5GE! ,M0SO9645;3-7UW$@+HYI-0T8M%]]OH?'UA98KRZ1WCXS"#Q>8$E>U M#9E3-:ZG!U'K@"F]Y@L9*G0>K]S+%2XR>U/>2'/6T^MVZHY=)011P[H;H]M6 MZ1YJ]!>>Y&+O,[;9;&EU9\CV#"*@OTOL"HQ^PPH06!D$*+WV=&!$P#AJ1* R!!4Q_M&99]F6\#(%&2R%ZPRT#=?"Q)M17^YGQZOEDF>VDX\38FS_@DP5_=. M6GH0? "F=!Z*-,0>T/3X3ZL_(Q7E 8$;MN18+FJ[V&]6+ 56PK*J7('085&Q M8)$$@0/L2R?BAJ%*BDJMKY6R6H8M1=+274%@M:6JOY481,7;'!F-0*N^/3;_ ME[OH41@CP&0'N\QU-V SJ7<%34T0&'08,TY6*BE26E^3'0Y=V+I_4+#V-BA8 M]PP*UB$."M9#!P5KKX,"M>MRF1+11MVNTF2-@443.]6NP>BPK#-BD0:%"^P/ M;#OJ$'2(\;':9K'LFGR5 -\4'J[$!TM) 9VS]3:[;-8+;MI$07#2YIY?X@S8@::K^'IT8?!T3"3!E)E MF%ICL0X\+,/IX[)[^1#'+R1-?Z+LE2X(SA@E<7F]Q79WJ5OO]JF;'MOM!V\ M<1!(#7$(/'XC@\9/,@JIL.IJF3>:OK%T2W/,BSGLW-9" 3JW] VV]1HHH!H ML3L#**G%J%3[FQ1>KEY1#[S*=R:!A83DCJ>(=YK69HI;M0%QTVD0FC=>K3ER M&"^741ZG<^9$ONLB>2%?<(XK?V"9(;GK"9Q=IO69FS9M0!AU&@3G:M8QOJ24!(6+SU;&*#4=*ZXV'Q0:GZ>=M MEE"2P9V2IG++@]5BFX>6)" >;+X '@HI4EIO/%QN"%^+[NY'SE[SQVH-6;!\ M@-HM'YV6VYQ8I0'QTN4/X$:%H#)&+?OK#Z#=80'T<@5(N+06J6-T0+,:-X8N M)&@@HU!%(A7@@YU:PS)OG>(61>4XVX$R*_A!7 M% TUKUCJTP=!U$"3.E=%6/O$NPA$,M+WJDK-!?GA85]+Y'BT;#&H#98;BB X M 6U!0^7F^PW\K>>W7:5)=)4R#%^%:6D<183(I[6RNN7JNT8W,-HM-V\J4INH0:$!L?86OP"%ARQ0 M(X\/C=[+]P4_^3"Z7&&.14^+1RP.XNTVSV2/*LS!5\P[@QS?BAA0 .V&1$=$ M0/@-L G=G"@B41'Z 97!J!'M\;PM.ZQ.2.+/^WOR0+B80O0B2PQ20[PWT^R,>6')5]>>I.'A)@KZ7X_5Y9]+]8?#1J0-$0GA4M"KAI"-MW_^_%-D?RY_ M:3:C :,\Z47O9-PU%[ZF@BABIWD1?",_<$3E@G*JH+],%IX;: M+XJ&>]'K5N=\$C6;@'J_4)%(]?EQN*UW;LQ"]]KMY7+9$O*9+*5ZTJU8IK * M1X:83&]K.UN=;7Z*XI>>^S4AFD:6E]"]E697#=?NIMGE>4NJ6;M[=M9I M__WQ;A3/:4J:3#AN,6V4I5PM5>4Z%Q<7[?S;TO3(:-;3N7MW,B8F#WMM,Y'7POW7+,V:[E"STVV>=UHKG31*^#E!)3E]I-/( M_;71V[9J?8F?4F+H8DY42ESV7UJ'\])S1:=7C3A=,-M(MWOVNFCB MUSTCLU[8_JF9ZUZ-J+W7_$)1387)%=_9 WM%Z,K87D63LB+7_HD.&F91W=AV29^ M'-%KZT/B_!AP,JM&>F "9-K!@%JI!I/J.ZICQ1:.30WB/YW3/1^G2\$_NVSN^[;RPV<_TX18 C^>"DA.%*+&(4' MJIA,[*5> ?@?&0/)7V"2]RA$9WXK$BCQK2DX1\('?B /$?> Z9CPPJN!/:;# MR"O,H=A1CH_Z%$@<'O&$.QHZ2K-1(1H/O+<(E#]*^@F2BQ:&H8BE6LB=Q\U]F=ES<]V727"( MKRD(#0E*7GJ"=+3 7">)1:8W?^Z8H)U0."K-P7-->$$(R'Q!Z+NGH>_"T:/D MJ[4R7Q#Z\]/0G\/1H^2LM3*QT??MQWLUEDO/K+;7&(H=)6>MD8@-/;_ZW*L' M)9]9L1*KCOQ1"2A^Q%0V+!8[!IN+/Z37EY90YHAI;;4X;-8/4AO"_V6+NKO, M:GLH=\0$-R04X\%D$7_WD,.W7.G !,H8):>ME(.!U45:4>+OQOL64*@HB6J5 M& 2F=]+-HX>!G:_!J^50AME#&0@HORIF MK!=]F::9V#S7\4RAB%'2Q* \!-PCR5G,#!.SC_8.4C'"JUE7V4%!HR2% M?F$(E!\4=1&G]M8\7S/F-C^H^^G4-Q*'[*'447+">J'X](=:9U2=&H.*4M!( MH*2'4-$88PZ-,SL,KCO=R=CMXO&,.$=64-XHJ:%/% +?3W*LB-M1.%JG$\G] M6U4J#:&441+!@#0$T'N^5",^,('"1POS M;4AN_[E*H\I%#K.%LZ0/ S<6<(,30JW!DP0$=O4:[OGSI/)UY>" M!@%GCR=0--H4P5?*^065(J M7X"J/.>"QQ2*'7$NTB,/;[UGL:AZ>STJ7CP2HNXK 86/."D9%HNX%LY0YS=[ MIN^((1LO0S'PE8#& '&",BP6=0V_ZMN+T4R&Y^(/#*'$$9?@5DI# SU*">GGF I E8 30L MB'GL22CP'BW(-'4;G&3\-)I;X?H^,_D[6ZV/P0<,P7+0\&!N,@4(1[P[TM\W MH-'D9OU(IU2Y)1!CNC(WMK&G\,T2H#@T1JAO1@)CJ C59?M(UYT]X-[,6WSC M?KFWS]HC_P-02P,$% @ &4J_5,.FVHFH'P (KX !( !T;3(R,318@L9;1:/89R>_^.^S;Y(9Y@KO.^Q4C M5U@AS#%=BSO=]RN!W\ENKOQW=WGI7<^'=M#6$>]7>KX_V,[G;V]O<[>EG.MU M\\;6UE9^B&U65*/M86J[8J%@Y+\=';;,'NO3+'>$3QV319UL[ES/'A^?1DW; MGLT33?&;<))2?FIH>&J-.\0;K^?5PT13/[5I137UPZ9]L\-QH(SJNUZ<^["&.5,D6BMGB>FR0K&!F8B#X MG.NZ-_>.LYDM&>$X4YN37"D^;E,18=QB$^@.YX0'T*-H_"R'33W6F3GP>AZ> MA@T#D>U2.H@:=ZAHRX;Z@1PW6S!B4,,3S[692.TCGZ1T,MW \;U1.OSZH>P6 M=A">/ST!?)DR=NWHM!FU!3XPKP'C;-"C@/FJB]4^Q_J%:/85? MN"*2S<[;N[1^A2N^2EGI5;C2!PQ7+D2]'M.]4KYB0'^P#/BOX0 B1S7 D$?M MIF.QX0$;715 1JU7C/+#QMV*C5OM,\>"__U]FW:O.M06["%#&;&A:H'GX4!< MF-3^SJC7<*PZ(/%*/3YL%89'O/#KZ//[]P^88GT/=K1^95QIZ:0&@Z\>,D;Q MJ@4[R<15\4H*8S6(D-\]9)PZPG*JQRI-@31S\+9KC8CP1S9[O](!0M\F1F'@ MDW/>AR;'[):/Y)@M5(#5?7?\]PIQ8-4P%>/; MJ02WLCNFN'?YQ!2_,ZN2Y.]70/IOMUV0<]21E!B')T&H*[OR^0)!&$\TBXQ7 M=K-9HYB=L?!\ OT(!*@"!@.93*@6J'.VA30F !HB+83MGE0G9G_ LZ&$R V% MM:(?^R :WZ\(WA_83(E#/55R<#6=< ,OG V:25K8RSDIN8!@03;.(U;["L9@OJN%WO\'_O ;_WTW".5[ MGWI=[FR3PLKNO__76"_LO,L/=FU*#1Y7':I?UG<'H'B* M ]!N^INVZ_MN?YN4\+M;;OD]U$R%?U82W=NN!X"K[GLV-:\)C$&$:W-KA^B' MX4CJN3%^CNHN*_@O4*;P[7AMB +],[:$?&(-*L>=YL MM$CUN$X:WVH?J\2<&U)$J!.WE MK8+R-++9NFL&:+NAJW=E1D[1V#WZQ3YL6;[7&7YT>C#<[]IP\?E6=C>S!Y,V MV[L\0KK[I*3\8,F<0G_&W/37?FKZ6PRE+)C=9Y(C"-"SQO$Y.6N+J[C7:\%,?>C7L^AH!* S)TV<)0!;V3VB M(U(R,@0'_1,"[DU7+TI6SJ.JB^5%LB$"B(&S,0@AT4X(-D7RTLF>)W0]4X%\,:,?Q4S_@YZ M?=JV&9"3;0/)FC)Y65B1GP?4LL+/#YXNANS(*S==VZ8# 9@,_Y*!8U]&(7PK MG.2&>3XWJ1V2.NQ+*'29_FOYH UK*M%5]7J4^Z"YL:V< L+);6L^6-XV2])SFVFCXX:6) MVGGV'/9)F1E28A#7(Z[?8Q[Y$7A<6-Q$P,#N>-?V5$J(QZ6,;.YUJ<-_R<_: MZG@6\?&@Q=7=$F).F&'+NY M\1)"8LA+U?\*G.Y:6"!!3F6%A,D"B2T8!U1>[N^)+B@3M)!BP"J)]1L3I%'5 M?),^G_JL6I;'A-"_#KG#C'1A6]O[^<.]I.8FYHH7)&Q3)E_9+98KRTM'%%RG MEN\QYL\0MYFI4+-QS\**Z0N[YO72_I[S?;-A/N'"BK PQR+[MNMZ\RB0UT9U MY;3-J<&?)]ZY>^ND;\V!Y[*MT_WUGZ72HK=F//7*;HWVVQZWNK.L\,QTP' K M;3E269]XI^ .@$*>X85TK!XOG5[[U2_7S^>%I .(\4,AJ-D+!/-],6/U4WQ6 M25O[J0M V)=\,-O_ZG<+5>NZQ)JGE47O9F)VL,F+1OGN>.@KX;)5O?[E);=# M3CW85#Z@-FD,F0GJ^(:1DP[8(TRLD55 #D'LK*4@X*7KZ'NC<;/8$[F\ZC$Z MFRB[7UL_OZRS4NVRO0"BC,^WLKMN;,P@PK4IIJIJB ]=,*).>ZYSIU-[61F< M?W>#C=K71>1*)^<$R#>+V=+Z/3[MD^_J."#\[__=+!H;.P*:VFR D!)'@II! MU\<.,&:VO$0!\[#\B,;_!O/S/B02RCVQ[1 M'[6L 91W2*U'G2ZSEI=:J$C((14^.9,)MK<8]__K&+?T"XG?8X0.P"(9>!Q] MQ+8[)&UFN[=(._@028IL9@](A]O NX0+8&2?.1;2E.\2P?N![5.'N8&P1T2 M2RTZ(]E5]W#;0+JN6).P;VV_60D_<>3 7A4P[LC8AA6@,;B)7KP M\C]I9LE, ^*HG_P]4>E]O7[T>/# M@?/4H:>"I+9UFQHQ'@">P^0 4/M1&U+#"^N/ DD'@B0 818$"_(;BA92+ M%'EM=FCO7S$>;FWW,7NVAT20H4E5I*Y[8GC65.G!&Y[W&=9 M7 S#D\6W'AWL$+V6Y"F$!Q6.K"^Z<.0Q31&94YM$;]MFNOB@?4./PAR(]UA:O$.0ME3+@.X#P@'W@R9L^I MDH=%E1H^<8(R#,!KF3,RBFU)<>E:[=;]:KD_VN[/_N.U6LQ;FIAS91=5&4:@ M6KYK7F> '3UR0^V D7\5>F;:M.MDWJ_ M_G&//=XY'F]J8D+8T:/3YMM>S5Z"2CJFPZ$_RP7;;U"9'U+N>6;4RJTAP@75A3V"'-1T+#5)& MVB,B;\;!!M<@^IFL2IP(OG-!*(@N,&=QD"[I>NZMWT/#=H 1>2J(Q3K<4<:WDI M81ZK4'\&4YI=D#MD1E: M+Z,@X>F*E$\EL'N@)9G-3!^TI./*4$<@F&P%6)9Y> FE13U+J"RY-2O84EJE M4; EKEASSRP6%G\W3EJ1A[HOYW%5'JEWX\3NSEE<%D]1J^S;0:T#C .),SQ*==G M[.!#IXRC_=$8?WR54AN,;M]SK<#T76]$CEU_L<5?3US!]B,0/N^ ;5-%60*" M1]7Q6%R8MBN4Z8_20U^UIVO'9$ I7AH$#:44F_ ,0$J-Y4[L%-$JML-:03"G M6HV:_,O8 5'ED.K XS98_>JNA RYY_P*R&M*PL.9)'ZX*CZ'-H;">3)$.LER M=2 N01M4NQY387T$^=2FLECI"%0$N$WQD?174?MHR.4E4!78F?9=D- 29UJE M -*Z6+4$0*6O@5"Y=]]=4#&))>A)3_&6B?%4")H"VYQZLE*+#7A>/[ @ST4S!N#@+=@6.@B M0FN]99MJRW+D-$K+ W(1$9-(4RL(!JZB+=B*OJ(5@.('Z"ZB^X&M8G%5"(/^ M*^- V= G?IE&AD3 *8W*)%S$I *H46:5,!3=F=A&F6F*R YI #$(:**V'2I, MCIDI2\+E!KY4N5+WJMM"=2-3QO^ )>\+_V5D1#Q&%I,$BL/(*&($%@5J!*;D M)AL/@_/^RRCD*H4,@MV&1Y1;(<($V-G0$G@6UY^1/ FPRY(]#V]8P3E!;L:Q M@.7H)AM/FMP&8!)59"=M%AD6B(I% KA0V"BN=^]P)0$[1#B";&,9V98L,O75"N:X']A@(?\&4=2D+0H<3K72H? R;*AG%2S@2+!\B0V':[P&.I0Q DI^UONC! M>)DST(3C 4?";"#UY!"^VU5!,F6-HQB0'_4 JQR]AM$:3.^P#D>#/)*=0.A: M8"(C3L,>WP.%%>)S ME?Q1;@<09:+>5J(P1TXF)2X<:1<V M7FT<*Y;Z)_!NN*2;N+FAX>K/LJ9"W:-$AP;_%H8<*_0T[[98,59[:Q'WU#_4 M#I7& U&@%#+J)ACJ!FSR2"V!O%4\PP#-ICQ[%>>>%).O$37$W8[9D)AI'1L) M ,BD<)PB]U57Q^&!\U?YVDPACHN !P.MA%7J%D%2*]+F$'0#+F48 P#[ 'B% M#9EGJM !;AQ\V5&1"0OHR+&$TN$@W2D75-HY(H"!-12P352J(GS!A8(A0O5Z M,8;C53X;="FH)<%)V2BMXDE"\>1EOJ/0:$)08/$H&Z-C6ONYX;.!:&:UUO6U6Q8*:*8#P8J4NY3C?<\X-)-D0$ MAUB7V-47:BB! M:V3!'A$\WJFB\T(R! MFK90M$.8S,FE2?LU:.2$\#9U&[ \)H%6 A99W;:U!346,"$>EY>X(/+"=UN: M2!%K: $:F;DP]P:%[BCLG, 03((L MLKPTQJ&JII/"*V6)&8)GDCCPEF*SU;VUN^RK& ?/&I'P?I]97!K$ (?'T2Q7 M2C&I'7(+.+'\@ECYY00?YRIIF_NBD)8>LGRF?$R)06[5@.YH)T:3%#\K;R"13TO%U,?NY/'WIL:Z+ M*+28,#T^B/LEDYHFLJE4@DOI9J$2C&"WRP"AQ!2(8,L%\!#UH&SEY;\J=A4: M^,K/$ 352/Q"3JE[/.:/4(Q'+U)).D#+2_&X(@PYD"%,93/#F"HZ#3O=&/9X MF_NDF#-(TJ.)3JTGH]PD%N3.3$6Y&[5$N'IY23O5:+*$!FD=&_BZD-<4^ MFD=C20 4='4N9!@Q?"H$\Z?JL.?(_;[DC)624NVQ-3R5BR.T#;8EI@WPKJKT M@ <'IK]QT0\;+22 -2,4.9A,BZA F]JMA$TY?P@O)I?G#9B0>+QDK/1DD"29 MH8C$8BR8(F*!E(LP@9,6Q5)091+.?YN96*4^,_6D;L>1#OXK<891J=(NZ*4.L&[3SIPXX97UXX$6!@S&'HKV+&Q7?'Y,QF(EE]=!&A.E K[9WE MI0[3:6_@8>8()EZ?D-(J/!9QI6"&\L()NVEA,FG M@]#0)JZ>GQ6E;U;3O593Z6^PFH H,:P$9%EG-AI[ DF=RECL.QO@OV M(>EX;I^$) ACY&7QIZHM#0/=T@$M5I L5<9*EPA$E-NYRSR5,VB!IH<@@5:TT]OQNK]$H[MI%!KYOV51%L(J,6:QPE_Y:7XCF!A-VH;IR2 MB4^)7_#R4?I%-SAKFUMS-983X-^4Z$M4HJ47 MKT3#VX+ ';#&C(C7'F 659)9>!"/?%2>XVM2BI-V\%011HH=C"R+&RRD]9J1 MQE*&5."G? 1_E.ZQE7/ 7ZAD*;YXR5)G6+D3Z/HX0".^0T)=@.Z) M'=*P6?C>'%+G'D/BAJ^K@X$+1"@#\JG]D,/ DJ:2%ZJ>ARR*K45:\URA5*:%-_5CY_B2$ M6)RIH,B0@;S%$MTP3/E@RMR4(>+7$!N>IUJH^%8M]%8M])LJ968J*%92%,]! M=>(5]Q-R(4.T$CAV RS4_!@(P;C#YTP^:6-.AE=<>RPBM+!"22ME09@$(HD0 M%Y\16;5=$=8,IR=2[Q!^F%%#-0G2-K8DSAR^O$0%.:(.E:?>PPY2NIVY(')] MTLB10_CHR2KM6H^S#I!=>/I<*T[0!3&#E+:Q,ALP(L+#T_B4YEA1/J$I[86E]".<^;0?P(@_CE!].J&"-7IBI0 M;171:*M0;7/R?9%[(YO>HK$;>:#[7 #2R7=&O==DU)[&"EC"B+Q(RL38@6(0 M;O>?ZDF7H>-4@FR>?$,GRIFV1+FR(*5-':8T5/I)OM,KS']SL*[#FL4<3#7@ MXZ/"J=WNG3VUEP8)2^'!!J4HR.)"L)0S5$'$^(MB)LP' &[L48:$WOQ=)8]R M?H^]R;V_3^YM_6Z(<<% C0V)2 >'UT-($OT['7+U,U?ACGH?D[6F)ICG9W+A M3P/0*ZG]O?=F9$W&B[[)6&_1O&QD_)-Z'_/$[9Z/6]N6L>C%U<<5_K-Y[Z$[ ME7H3*24]#Z\;Z_G^0&SG\[>WMSG!S%S7O(&&L54RBI5BT2ALK1N%O%4J5]:+!8L-BT:NY_]ZQT6E!N^$O<]86MWBB44XV>&7NVH'GO"._6Y"%Q&0!OXF*I\O/K MH!W)/I8%KF+JR+*T%(X*<6SN,/)M[^R06*X9R#/RS^YH//1Z2R,M=3#W[993 M1N3B;J]<%$+^1C;6R!ZK8)$QYZE.[LNS4I]=,E=X&GL-%CXA@,+"E MU4?Q_J@PQ!5[B6L(@(B DW?]Z2);HJ^$N!-,ZI@8.K%3,5RZOWS]]8Q9Z)[\,:+$Q%NF)5[-IFR ML#:GXXKIY?G#5:S_-&\Y2 U3/E%_2QUJA@:!ZY MH,X*3-P&#C)A1$P:R((7C+"KFGY=_**+8EQUO4&;]:C="06B%+>Z 4K@ $ON MY' T\'NN!WQA_;E0>UPO3^KM!T,R4S5/6#B)MZC-/WSJ:W/BR[59QP^M .NA MXR]2_8?H3MH "!1@!+]\OU)\,'X770G\L5$[.*J>-Q"TTX_5LZ-JK7%QWJQ5 M#UO@Y1S7IA(-XU>*O;2]B^BK4EBH&3=['Q\+8.F%PU?>>&( 7RX1+7+=X+ZR M;80C?K'# O9ID3#NC;;O@.@^(_!/0)P7>81RHJKK_Q]U+8SM7SU0BE00D#=J M>5$;\R*!"NLH$92PE/*!KPM>Y 3B?[L4_#_1]? M"@>W/ZJ?>XW\YY/1L&+[@\;9"?]Q=O%5-*^_-8PB+S7ZHU^7EZ?KYNCLAGZ] M/;/+7^Q^Q^[W]OBG_99Q_./SR&&7'^O5RZ!H]-9[MU7W^ /'>^;D>^(^M&M>[37_TY'F]>5VF'):/=&7P]:Y^?B\N>Q_?U38W#MU3H< M_-[*^IEW,?ID]'RKN_'=WOADT^.@:]R4::-;6F\-6/O+EV'QS&E]:'?=T?GG M;^OUUL]6[:-5,KKY'_WFT>:OQO?2.C=;!S^_!OGCR](OXZC&A_RR$'S^N-7. M?][;][]\.KM]_UZAY/\ 4$L#!!0 ( !E*OU1U\4&NT0H +HU 5 M=&TR,C$W,38W9#%?97@S+3$N:'1M[5MK4QLY%OWN*O\'K6LGE:DRV":;V1WP M4&5L$US+J\"9[-36?I"[U;:2?HW4#?'^^CU74K<;: R$D"6/? !;W2U=79U[ M[KFW2?]@>G2XVVST#\:#$7XS^M>?3J:'X]U^Q_[&U8Z[W-\[&?W!SJ=_'(Y_ M:P5)G&VS7C?-V%1&0K-C<NI.1\D;5VQQ\7G)V>#Z>3DV-YQLN_N/!@/ M_WE$]YT>#,Z.!L/QVRF>.SQOTU.;_<[>[E?BR;6+P&<#N&1X.&:3;V9/^R?' MT^K,&UK^5]CI6[O3A6 QCP1+ I8M1+/A)2I-%,]D$C.IV7 AO \1SP0[77 5 M<4_DF?1X"!,FL;?)7N(A]B+T_\R3G?[;W>'JZ7[G[>X+92[\#("0%4_MS_5; M+;S]12RI .DID?0^UYD,EFY0QKZ@2;N;KV7\Q/ *19#5+TN0XKZOA,9$,O;" MW)?QG.E,"9&UFXTXCV9"M9DGLV6;\=AG7I+']-EBD"DQEQIN%#Y& ND5X&3# M*C9C,W2>$39Q?21"?LF5(-!>OW>JX":,1"F/L4QOJ_LKJ$WQ>$X3&+/8$-;0 M/.]D&,'<+($SAL8N&B4/#;G.0M&N6;+WZS^ZO4UV+9:J^^!S>*AF&\W&K?O@ M&=.YMRA<2?N:KMO7YC<'L=I@^AZC*!AR&:"90D3\1Q H] M'AAP%.0AXQZ I^B7O"",!_ARN9! 5H7J-8Q;TBR)FO,8I.F;P$3TNGLPD,,P M90QX(V*A>'C5D$-^61AX \Q/A]O,Z4Y4HY7FV2)0!& KMPH2_=C>[/98"W^9> M*VMN+AKP2(;+[;MJI$(/.:E!LHB6;3;.:=TG%495*#U*#CTKO+&M]7 ;?_0$ M3. X8QR09B#+7$*0 . '&H(.N*IEE(@;7Q;JB M.A=)B/QM6)##TO=@8:MMZ:(A8IOS,;'.\,%H=D.M3T02I,<@5L1J//4N!<9(1>D(9 78%=@![ M8O;DDH ,? ="*(XB%CHDHAB&*6YK)IEI(]3=0K39)VZKK 72%^VU/#;:OK=P.Q(B W_K4G48 MUBXR0*F+%R+TRSY#&G)/V!R#N*MDF5O:$V7)Z L-+A)P:YO)P(2Z3BKSM,FH1W>"(+]YKSJ7?4+P%VO^96.#[4O :)N=\KG8 MP<1_Y@(BGA))0^ M##B].I\K%U8>Z7>P9LWR,R7XAXV9@&*'C:FQN6K2+S46D9G5):^Q71W_W(NX MK!^O6%KQ9X<<:GWX#<&JGIZ_-WZ^WAZ!!A'J0FA+UK;Z!-=0%R_#:BQ0260_ M$2.YWSP2L>]429MY"]/.!OLZ<4(/E[*!Q%+&95Q(:)('=RG MUD##C ,/_5W!$G MEZ@^%#*5$C+F069L$=I3E@CUDN5SKG<6;S MQQV^IAW+3)MM49:!@R+3L-5FUW;/YJRI0(.QS5$+'H1I*/E,AI52O%JR-!LU-0NA D 35!I9 MV75'%<%JBXB4*PXHI0OV\N\_TP#@I-T&7L[,R OZOM-L]+I;U;*C3=BD+YI> M=A6A7" 4^-=YFH8B(F3X7[8I]8Q[E+4M\?:ULVLV[G=X]F18[V^OBX.I>2?# MUKV267>(M@*NGB+QLB^B&(G4,&!!N%4.!(M5&YJF?#9-_O))^P9)=%;,#A.HGQHX_9T*) @<5!$MDKZ )"T31QR>0L 8UGB7 4/.E>7[3+K%)K!EA6P;:Z$\7N[V;!-O>!*2J*-^< "$2\P@SDJG*%6 M+? V9'2V,.>A%OS^#:G3PVL%9<-2K]1Q%O6@G'TT[VB\#P_2 R<%>2$UG?5U>(.FO^@H((IW2BN:] M1KBL8(."B/L(2BUH/ A(P!#XK7I)C-3,5MWB.G@ "_;/*=05)89#QQ$3+JN2 M,PE<2\)3!#LK6*LYEQ8OUC!3VE7J.@VF_XZ02ZWJL@(9X6+#+I*ZY&<#K]6L MGIX8\:Z3VVDK.9C2;>ZBNM87= M3(#Y COGJQXDCL^7ADZ/^++-MKI;6Y\OX-?ZYR$'-1WLH9(;C@\/ST\'P\GQ MF]]:W9;Y?CH8C8KOSMA+Z6<+LK;[TT/DMHM++PE#GFH$0/&I91#%CM!(+0*E$]'I>W3T6J0#4_(]./?6EMWO:Q Z7K'WS4VJ[K@AL5WTNRG_3F-1=05 M4SJZPP8AC]D>UXO''XY1.VVOK&+/Q*PI%1G;;+B0(F!CPTRDRDZ< MR*FWLF.B_YDQTM.TK?[=G^R>F]=.5%.8+ D6WY0[:]VF$GJ7D#M\T..5+?LU%Q7T@;W7(B'?J_5_8_8]'_V?H? M4$L#!!0 ( !E*OU00DS"=C"X ),^ 0 5 =&TR,C$W,38W9#%?97@S M+3(N:'1M[5UIG[1\^0([/;2J^5Q!$;8)D8"/\#J\<<"+J+: M1153BV2]7_]RNTLM(+38!J29B+8-5-TM;][,DR?SOOXP/#E^L[_W^D.[>01_ M>OB_U\/.\+C]YO7/_"=\^[-\_?IM[^BS-QA^/F[_\]$TCK)7WO-GB\P;!G.5 M>EUUX?7CN1\U^(.&-U!),'T$#\*C'_5SIK]L0/@S/X:*RB3"6/WOPC&J6+PV_94A*N?WR[5 M*=LTTHF?J8GGIUX\]4[\2^_E\X;WXMF+I7IE,\?FZ/?_>O+$>Q>H+3+_[R2C.LGC^ROL-/QO% MR40EYK.WH3_^XCV'QM,X#";0@<(8GJ3!_RD>2-T$F":HT6,$&EK04-V7_E;S4AS==^JILPP_XSKPU-_)4A=EA___30^E MYMOCMM=[Y[5ZW6&[._P!:IM:XWZTVL?''YM'1YWN^W\^>O:(_CWXV&SI?TN/ M+H))-L/I??;3(UJ3U\.^_LYM+U136-)SE63!V _UI[RVA]YU#"^VYXY@EK _ MW7\^>OFHKD&C8C_6[;]G5?%Z]*;9!\T+0^_P='C7^]\U&G(G_=NUTGOWKM-J M#[[?8,"\/L+_]+^O("QIY-&;0;LU[/2ZWO.GW$?WO]37-=[1;[_O#(;M/IB) M/)]7/RC&\_--G8X7MYB.WO!#N^\9R=KPJ;A[%?%]=JY11#NBB4[:[2&<&P,\ MW ;#7NM?'WK'1^W^@VJZE6IJ=KN?FL>>GMR-WXW?5#$-/K9;G9V:C9>WF(W3 M'D["]L_!+[>8@__]U.M_.EE[#EYLZAS\>HLYZ((/G9/OMF!TQ9(XZ?9#"WH/E?.^7W[]R9W=M;:C??CE3QNL MKFYCX)\TN\WWH* \[3UNO*;ZME8^(E(?T>LYXB#WMD_&;6S]8;_=''SJMW= M)FYC[<,[^NUAL_]Y[6GX=5.GX5;PY�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end